C
Carlos Gomez-Martin
Researcher at CEU San Pablo University
Publications - 41
Citations - 1702
Carlos Gomez-Martin is an academic researcher from CEU San Pablo University. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 13, co-authored 33 publications receiving 1406 citations.
Papers
More filters
Journal ArticleDOI
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
Bruno Sangro,Carlos Gomez-Martin,Manuel de la Mata,Mercedes Iñarrairaegui,Elena Garralda,Pilar Barrera,Jose I Riezu-Boj,Esther Larrea,Carlos Alfaro,Pablo Sarobe,Juan José Lasarte,Jose Luis Perez-Gracia,Ignacio Melero,Ignacio Melero,Jesús Prieto,Jesús Prieto +15 more
TL;DR: Tremelimumab safety profile and antitumor and antiviral activity, in patients with advanced HCC developed on HCV-induced liver cirrhosis, support further investigation.
Journal ArticleDOI
Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab
Carlos Gomez-Martin,Jose Carlos Plaza,Roberto Pazo-Cid,Antonieta Salud,Francesc Pons,Paula Jiménez Fonseca,Ana Leon,Maria Alsina,Laura Visa,Fernando Rivera,M. Carmen Galan,Elena del Valle,Felipe Vilardell,Mar Iglesias,Soledad Fernández,Stefania Landolfi,Miriam Cuatrecasas,Marta Mayorga,M. Jose Paulés,Pilar Sanz-Moncasi,Clara Montagut,Elena Garralda,Federico Rojo,Manuel Hidalgo,Fernando López-Ríos +24 more
TL;DR: The level of HER2 gene amplification significantly predicts sensitivity to therapy and overall survival in advanced gastric cancer treated with trastuzumab-based chemotherapy.
Journal ArticleDOI
Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation
Carlos Gomez-Martin,J. Bustamante,J.F. Castroagudin,Magdalena Salcedo,Elena Garralda,M. Testillano,Ignacio Herrero,Ana Matilla,Bruno Sangro +8 more
TL;DR: The coadministration of sorafenib and an mTOR inhibitor could be effective despite notable toxicity in patients with post–liver transplant HCC recurrence not suitable for radical therapy.
Journal ArticleDOI
HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer
Carlos Gomez-Martin,Elena Garralda,M José Echarri,Anabel Ballesteros,Alberto Arcediano,José Luis Rodríguez-Peralto,Manuel Hidalgo,Fernando López-Ríos +7 more
TL;DR: Her2 gene amplification approaches might be an optimal HER2/neu testing strategy for the selection of HER2+ GC patients who are candidates to be treated with anti-HER2 therapies.
Journal ArticleDOI
Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer
Cristina Grávalos,Carlos Gomez-Martin,Fernando Rivera,I. Alés,Bernardo Queralt,Antonia Márquez,Ulpiano Jiménez,Vicente Alonso,Rocio Garcia-Carbonero,Javier Sastre,Ramon Colomer,Hernán Cortés-Funes,Antonio Jimeno +12 more
TL;DR: Trastuzumab in combination with cisplatin is an active regimen and has a favourable toxicity profile in advanced HER2-positive gastric or gastroesophageal cancers.